Cargando…

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin lymphoma, which is curable in the majority of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) immunochemotherapy. However, the therapeutic mechanism of R-CHOP has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ran, Chen, Zhi, Wang, Shujun, Zhao, Gang, Gu, Yan, Han, Qi, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755150/
https://www.ncbi.nlm.nih.gov/pubmed/31485671
http://dx.doi.org/10.3892/mmr.2019.10627
_version_ 1783453169394647040
author Liu, Ran
Chen, Zhi
Wang, Shujun
Zhao, Gang
Gu, Yan
Han, Qi
Chen, Baoan
author_facet Liu, Ran
Chen, Zhi
Wang, Shujun
Zhao, Gang
Gu, Yan
Han, Qi
Chen, Baoan
author_sort Liu, Ran
collection PubMed
description Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin lymphoma, which is curable in the majority of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) immunochemotherapy. However, the therapeutic mechanism of R-CHOP has not been elucidated. The GSE32918 and GSE57611 datasets were retrieved from The Gene Expression Omnibus database. The differentially expressed genes (DEGs) associated with R-CHOP therapy were identified using limma. Combined with prognostic information in GSE32918, DEGs found to be significantly associated with prognosis were selected using univariate Cox regression analysis and a risk prediction model was constructed. Based on this model, the samples in the training set (GSE32918) were divided into high and low risk score groups according to the median risk score. A total of 801 DEGs were identified between the R-CHOP treated DLBCL and primary DLBCL samples, from this 116 prognosis-associated genes were selected. Using Cox proportional hazards model, an optimal combination of 12 genes [including calcium/calmodulin dependent protein kinase I (CAMK1), hippocalcin like 4 (HPCAL4) and ephrin A5 (EFNA5)] was selected, and the sample risk score prediction model was constructed and validated. The DEGs between high risk score and low risk score groups were significantly enriched in functions associated with ‘response to DNA damage stimulus’, and pathways including ‘cytokine-cytokine receptor interaction’ and ‘cell cycle’. The optimal combination of the 12 genes, including CAMK1, HPCAL4 and EFNA5, was found to be useful in predicting the prognosis of patients with DLBCL after R-CHOP treatment. Therefore, these genes may be affected by R-CHOP in DLBCL.
format Online
Article
Text
id pubmed-6755150
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-67551502019-09-25 Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma Liu, Ran Chen, Zhi Wang, Shujun Zhao, Gang Gu, Yan Han, Qi Chen, Baoan Mol Med Rep Articles Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin lymphoma, which is curable in the majority of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) immunochemotherapy. However, the therapeutic mechanism of R-CHOP has not been elucidated. The GSE32918 and GSE57611 datasets were retrieved from The Gene Expression Omnibus database. The differentially expressed genes (DEGs) associated with R-CHOP therapy were identified using limma. Combined with prognostic information in GSE32918, DEGs found to be significantly associated with prognosis were selected using univariate Cox regression analysis and a risk prediction model was constructed. Based on this model, the samples in the training set (GSE32918) were divided into high and low risk score groups according to the median risk score. A total of 801 DEGs were identified between the R-CHOP treated DLBCL and primary DLBCL samples, from this 116 prognosis-associated genes were selected. Using Cox proportional hazards model, an optimal combination of 12 genes [including calcium/calmodulin dependent protein kinase I (CAMK1), hippocalcin like 4 (HPCAL4) and ephrin A5 (EFNA5)] was selected, and the sample risk score prediction model was constructed and validated. The DEGs between high risk score and low risk score groups were significantly enriched in functions associated with ‘response to DNA damage stimulus’, and pathways including ‘cytokine-cytokine receptor interaction’ and ‘cell cycle’. The optimal combination of the 12 genes, including CAMK1, HPCAL4 and EFNA5, was found to be useful in predicting the prognosis of patients with DLBCL after R-CHOP treatment. Therefore, these genes may be affected by R-CHOP in DLBCL. D.A. Spandidos 2019-10 2019-08-29 /pmc/articles/PMC6755150/ /pubmed/31485671 http://dx.doi.org/10.3892/mmr.2019.10627 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Ran
Chen, Zhi
Wang, Shujun
Zhao, Gang
Gu, Yan
Han, Qi
Chen, Baoan
Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title_full Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title_fullStr Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title_full_unstemmed Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title_short Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
title_sort screening of key genes associated with r-chop immunochemotherapy and construction of a prognostic risk model in diffuse large b-cell lymphoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755150/
https://www.ncbi.nlm.nih.gov/pubmed/31485671
http://dx.doi.org/10.3892/mmr.2019.10627
work_keys_str_mv AT liuran screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT chenzhi screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT wangshujun screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT zhaogang screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT guyan screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT hanqi screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma
AT chenbaoan screeningofkeygenesassociatedwithrchopimmunochemotherapyandconstructionofaprognosticriskmodelindiffuselargebcelllymphoma